Lynx1 Capital Management LP
DORADO, PR · CIK 1910456 · 13F filing filed 2024-08-14
SEC-registered investment adviser since 2023 · limited partnership
- Assets managed$626.7m
- Staff5 · 4 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (1 hedge) · $576.8m gross assets
- Form ADV · 2026-03-31SEC adviser record
- Legal entityLYNX1 CAPITAL MANAGEMENT LP (US)
- Kindhedge funds, private equity, futures
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 1
$277.2m
reported value
-28.6% vs Q1 2024
17positions
98.9%in top 10
7 new
5 added
3 reduced
6 sold out
vs Q1 2024
This report includes the holdings of 1 other manager that shares the investment decisions:
- Lynx1 Capital Advisors LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| MERUS N V MRUS | $71.4m25.76% | Reduced -302.3k |
| STOKE THERAPEUTICS INC STOK | $70.1m25.27% | Added +1.5m |
| GH RESEARCH PLC GHRS | $46.3m16.69% | Added +656.2k |
| C4 THERAPEUTICS INC CCCC | $31.8m11.47% | Added +3.2m |
| TSCAN THERAPEUTICS INC TCRX | $30.6m11.03% | Unchanged |
| CULLINAN THERAPEUTICS INC CGEM | $6.6m2.37% | New |
| ALLOGENE THERAPEUTICS INC ALLO | $5.2m1.87% | New |
| LONGBOARD PHARMACEUTICALS IN COM | $4.5m1.63% | New |
| PASSAGE BIO INC COM | $4.0m1.45% | Added +211.8k |
| CABALETTA BIO INC CABA | $3.7m1.33% | Reduced -1.6m |
| IBIO INC IBIO | $1.8m0.64% | Added +240.8k |
| BIONOMICS LIMITED ADS | $459.9k0.17% | Reduced -214.8k |
| PIERIS PHARMACEUTICALS INC COM NEW | $426.8k0.15% | New |
| KINIKSA PHARMACEUTICALS INTL KNSA | $177.4k0.06% | New |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $157.1k0.06% | Unchanged |
| KORRO BIO INC KRRO | $128.7k0.05% | New |
| VYNE THERAPEUTICS INC COM | $31.9k0.01% | New |
Sold out since Q1 2024
| Security | Value then |
|---|---|
| ALPINE IMMUNE SCIENCES INC NVLS | $89.3m2.3m shares |
| SILENCE THERAPEUTICS PLC SLN | $11.4m526.6k shares |
| AUTOLUS THERAPEUTICS PLC AUTL | $8.9m1.4m shares |
| KINNATE BIOPHARMA INC KNTE | $5.3m2.0m shares |
| NEKTAR THERAPEUTICS | $1.9m2.1m shares |
| PIERIS PHARMACEUTICALS INC | $1.6m8.8m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| PASSAGE BIO INC 13D · filed 2026-07-02 | 21.0% |
| GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 | 19.3%≈ $354.0m |
| NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 | 16.3%≈ $3.8m |
| TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 | 13.1%≈ $20.1m |
| KORRO BIO INC KRRO · 13G · filed 2026-04-02 | 10.7%≈ $20.3m |
| C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 | 10.0%≈ $63.1m |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 | 9.8%≈ $105.0m |
| STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 | 6.5%≈ $132.1m |
| IBIO INC IBIO · 13G · filed 2026-08-14 | 5.4%≈ $4.9m |
| PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 | 5.4%≈ $10.9m |
| AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 | 5.1%≈ $111.8m |